Novo Nordisk A/S is selling €4.65 billion ($5 billion) in bonds to fund plans to ramp up production of its blockbuster drugs, ...
Last year was called the year of Ozempic, though it was also a year of Ozempic backlash and Ozempic shortages, which could persist for years. Even so, we appear very far from a peak for GLP-1 ...
The Danish firm - controlled by the world's biggest charitable foundation - became Europe's biggest company by stock market ...
The U.S. Senate will investigate the price of Novo Nordisk's popular weight loss and diabetes drugs Ozempic and Wegovy. Sen. Bernie Sanders asked Novo Nordisk's CEO in a letter how the price of ...
The Senate Committee on Health, Education, Labor, and Pensions is launching an investigation into the prices of popular weight loss drugs Wegovy and Ozempic. Senator Bernie Sanders sent a letter to ...
Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on ...
Melissa McCarthy brushed off Barbra Streisand's backhanded Ozempic compliment as she hit the red carpet at the Unfrosted premiere in Hollywood on Tuesday. Earlier this week, Babra sparked ...
As Ozempic and Wegovy revenue have surged at Novo, grantmaking has kept pace. In 2023, the Novo Nordisk Foundation awarded a record $1.3 billion to projects related to innovation and science.
Three years ago injecting yourself skinny seemed positively futuristic. Now, everyone from Oprah Winfrey and Elon Musk to your local hairdresser are cashing in on Ozempic’s weight loss benefits.
Medicare Part D, which provides prescription drug coverage, will now cover the weight-loss medication Wegovy in cases where the patient is at risk of a heart attack or a stroke. Medicare ...
Goldman Sachs said Amgen's experimental GLP-1 drug could have peak sales of $5 billion, or 5% of the estimated $100 billion weight loss drug market.
About 3.6 million Medicare enrollees may qualify for coverage of the anti-obesity drug Wegovy, according to a KFF analysis released Wednesday. But it could wind up costing Medicare nearly $3 ...